Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: HRC

Gene summary for HRC

Gene summary.

Gene information	Species	Human
	Gene symbol	HRC
	Gene ID	3270
	Gene name	histidine rich calcium binding protein
	Gene Alias	HRC
	Cytomap	19q13.33
	Gene Type	protein-coding
	GO ID	GO:0001932
	UniProtAcc	P23327

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
3270	HRC	Pt13.b	Human	Liver	HCC	2.35e-06	1.72e-01	0.0251
3270	HRC	S014	Human	Liver	HCC	5.22e-15	5.63e-01	0.2254
3270	HRC	S015	Human	Liver	HCC	3.91e-22	1.14e+00	0.2375
3270	HRC	S016	Human	Liver	HCC	4.86e-15	5.10e-01	0.2243

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Liver		HCC: Hepatocellular carcinoma
Liver		NAFLD: Non-alcoholic fatty liver disease

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:005109814	Breast	IDC	regulation of binding	57/1434	363/18723	1.59e-07	8.76e-06	57
GO:005109914	Breast	IDC	positive regulation of binding	30/1434	173/18723	1.96e-05	4.86e-04	30
GO:000164912	Breast	IDC	osteoblast differentiation	35/1434	229/18723	6.64e-05	1.35e-03	35
GO:006056212	Breast	IDC	epithelial tube morphogenesis	44/1434	325/18723	1.58e-04	2.73e-03	44
GO:000150311	Breast	IDC	ossification	50/1434	408/18723	6.51e-04	8.04e-03	50
GO:003514812	Breast	IDC	tube formation	23/1434	148/18723	8.79e-04	1.02e-02	23
GO:000183812	Breast	IDC	embryonic epithelial tube formation	19/1434	121/18723	2.10e-03	1.97e-02	19
GO:00721756	Breast	IDC	epithelial tube formation	19/1434	132/18723	5.63e-03	4.08e-02	19
GO:00160557	Cervix	CC	Wnt signaling pathway	98/2311	444/18723	4.82e-09	4.65e-07	98
GO:01987387	Cervix	CC	cell-cell signaling by wnt	98/2311	446/18723	6.16e-09	5.58e-07	98
GO:00301117	Cervix	CC	regulation of Wnt signaling pathway	76/2311	328/18723	3.05e-08	2.08e-06	76
GO:005109810	Cervix	CC	regulation of binding	80/2311	363/18723	1.32e-07	6.42e-06	80
GO:00608287	Cervix	CC	regulation of canonical Wnt signaling pathway	58/2311	253/18723	1.83e-06	5.89e-05	58
GO:00600707	Cervix	CC	canonical Wnt signaling pathway	66/2311	303/18723	2.47e-06	7.35e-05	66
GO:005109910	Cervix	CC	positive regulation of binding	42/2311	173/18723	1.07e-05	2.33e-04	42
GO:00433939	Cervix	CC	regulation of protein binding	42/2311	196/18723	2.27e-04	2.55e-03	42
GO:00016497	Cervix	CC	osteoblast differentiation	47/2311	229/18723	2.88e-04	3.11e-03	47
GO:00320927	Cervix	CC	positive regulation of protein binding	21/2311	85/18723	1.27e-03	1.01e-02	21
GO:0045667	Cervix	CC	regulation of osteoblast differentiation	29/2311	132/18723	1.32e-03	1.05e-02	29
GO:00301784	Cervix	CC	negative regulation of Wnt signaling pathway	35/2311	170/18723	1.52e-03	1.17e-02	35

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

HRC

SNV

Missense_Mutation

novel

c.751G>A

p.Asp251Asn

p.D251N

P23327

protein_coding

tolerated(0.12)

possibly_damaging(0.685)

TCGA-A2-A0SY-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

arimidex

HRC

SNV

Missense_Mutation

novel

c.1345N>C

p.Glu449Gln

p.E449Q

P23327

protein_coding

tolerated(0.3)

benign(0.067)

TCGA-A2-A3Y0-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

HRC

SNV

Missense_Mutation

c.1431N>C

p.Leu477Phe

p.L477F

P23327

protein_coding

tolerated(0.12)

benign(0.044)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HRC

SNV

Missense_Mutation

c.1758N>G

p.Ile586Met

p.I586M

P23327

protein_coding

deleterious(0)

possibly_damaging(0.854)

TCGA-AO-A1KR-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

HRC

SNV

Missense_Mutation

novel

c.811N>T

p.His271Tyr

p.H271Y

P23327

protein_coding

tolerated(0.06)

probably_damaging(0.982)

TCGA-BH-A0B6-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

HRC

SNV

Missense_Mutation

rs766836022

c.1951N>A

p.Glu651Lys

p.E651K

P23327

protein_coding

deleterious(0)

possibly_damaging(0.885)

TCGA-C8-A1HM-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

doxorubicin

HRC

SNV

Missense_Mutation

novel

c.1600G>A

p.Glu534Lys

p.E534K

P23327

protein_coding

deleterious(0)

possibly_damaging(0.587)

TCGA-D8-A1Y1-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

tamoxiphen

HRC

SNV

Missense_Mutation

c.68N>A

p.Pro23His

p.P23H

P23327

protein_coding

deleterious(0)

possibly_damaging(0.543)

TCGA-E2-A158-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

arimidex

HRC

SNV

Missense_Mutation

novel

c.704G>C

p.Gly235Ala

p.G235A

P23327

protein_coding

tolerated(0.51)

benign(0)

TCGA-C5-A1M6-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

HRC

SNV

Missense_Mutation

rs563550433

c.872G>A

p.Arg291His

p.R291H

P23327

protein_coding

tolerated(1)

benign(0)

TCGA-EA-A410-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1